History of the Spanish Association of Telecommunication Engineers (Asociación Española de Ingenieros de Telecomunicación, AEIT)

The Spanish Association of Telecommunication Engineers (AEIT) is a private non-profit organization that was established 83 years ago. Since it was created, the AEIT has been defending this profession, the telecommunication engineers, and the way engineering has to be done in order to improve quality of communication services, in a direct way, and to develop our society and enhance the economy, in an indirect one. To meet that objective, well prepared professionals who are able to design networks and services were needed. The AEIT has been involved in reaching it. Chronological order will be followed in this paper, completed by some relevant aspects, which will give a general view of all the things that the AEIT has done during its life

"Cuerpo de Telégrafos": First Attempts to Create a Professional Body for Electrical Communications in Spain

The Body of Telegraphists ("Cuerpo de Telegrafos", in Spanish) was established in Spain in 1856 in order to operate the electric telegraph service and later to develop a national-wide telegraph network. The origins of this professional body and the way it was formed with people from the optical telegraphy field of activity will be described. It will also be explained how these people were educated in techniques and methods related to electrical telegraphy. In addition, it will be described how the creation of the Body of Telegraphists caused a conflict with the Body of Civil Engineers, which was the responsible for the development of the optical telegraph network

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research

The zCOSMOS 20k group catalog

We present an optical group catalog between 0.1 ≲ z ≲ 1 based on 16,500 high-quality spectroscopic redshifts in the completed zCOSMOS-bright survey. The catalog published herein contains 1498 groups in total and 192 groups with more than five observed members. The catalog includes both group properties and the identification of the member galaxies. Based on mock catalogs, the completeness and purity of groups with three and more members should be both about 83% with respect to all groups that should have been detectable within the survey, and more than 75% of the groups should exhibit a one-to-one correspondence to the "real" groups. Particularly at high redshift, there are apparently more galaxies in groups in the COSMOS field than expected from mock catalogs. We detect clear evidence for the growth of cosmic structure over the last seven billion years in the sense that the fraction of galaxies that are found in groups (in volume-limited samples) increases significantly with cosmic time. In the second part of the paper, we develop a method for associating galaxies that only have photo-z to our spectroscopically identified groups. We show that this leads to improved definition of group centers, improved identification of the most massive galaxies in the groups, and improved identification of central and satellite galaxies, where we define the former to be galaxies at the minimum of the gravitational potential wells. Subsamples of centrals and satellites in the groups can be defined with purities up to 80%, while a straight binary classification of all group and non-group galaxies into centrals and satellites achieves purities of 85% and 75%, respectively, for the spectroscopic sample

Investigating the relationship between AGN activity and stellar mass in zCOSMOS galaxies at 0 < z < 1 using emission-line diagnostic diagrams

Context. Active galactic nuclei (AGN) are thought to play an important role in galaxy evolution. It has been suggested that AGN feedback could be partly responsible for quenching star-formation in the hosts, leading to transition from the blue cloud to the red sequence. The transition seems to occur faster for the most massive galaxies, where traces of AGN activity have been found as early as at z &lt; 0.1. The correlation betweenAGN activity, aging of the stellar populations, and stellar mass still needs to be fully understood, especially at high redshifts. Aims. Our aim is to investigate the link between AGN activity, star-formation, and stellar mass of the host galaxy at 0 &lt; z &lt; 1, looking for spectroscopic traces of AGN and aging of the host. This work provides an extension of the existing studies at z &lt; 0.1 and contributes to shed light on galaxy evolution at intermediate redshifts. Methods. We used the zCOSMOS 20k data to create a sample of galaxies at z &lt; 1. We divided the sample into several mass-redshift bins to obtain stacked galaxy spectra with an improved signal-to-noise ratio (S/N). We exploited emission-line diagnostic diagrams to separate AGN from star-forming galaxies. Results. We found an indication of a role for the total galaxy stellar mass in leading galaxy classification. Stacked spectra show AGN signatures above the log M -/M™ &gt; 10.2 threshold. Moreover, the stellar populations of AGN hosts are found to be older than star-forming and composite galaxies. This could be due to the the tendency of AGN to reside in massive hosts. Conclusions. The dependence of the AGN classification on the stellar mass agrees with what has been found in previous research. Together with the evidence of older stellar populations inhabiting the AGN-like galaxies, it is consistent with the downsizing scenario. In particular, our evidence points to an evolutionary scenario where the AGN-feedback is capable of quenching the star formation in the most massive galaxies. Therefore, the AGN-feedback is the best candidate for initiating the passive evolutionary phase of galaxies

The radial and azimuthal profiles of Mg II absorption around 0.5 < z < 0.9 zCOSMOS galaxies of different colors, masses, and environments

We map the radial and azimuthal distribution of Mg II gas within 200 kpc (physical) of 4000 galaxies at redshifts 0.5 1. We investigate the variation of Mg II rest-frame equivalent width (EW) as a function of the radial impact parameter for different subsets of foreground galaxies selected in terms of their rest-frame colors and masses. Blue galaxies have a significantly higher average Mg II EW at close galactocentric radii as compared to the red galaxies. Among the blue galaxies, there is a correlation between Mg II EW and galactic stellar mass of the host galaxy. We also find that the distribution of Mg II absorption around group galaxies is more extended than that for non-group galaxies, and that groups as a whole have more extended radial profiles than individual galaxies. Interestingly, these effects can be satisfactorily modeled by a simple superposition of the absorption profiles of individual member galaxies, assuming that these are the same as those of non-group galaxies, suggesting that the group environment may not significantly enhance or diminish the Mg II absorption of individual galaxies. We show that there is a strong azimuthal dependence of the Mg II absorption within 50 kpc of inclined disk-dominated galaxies, indicating the presence of a strongly bipolar outflow aligned along the disk rotation axis. There is no significant dependence of Mg II absorption on the apparent inclination angle of disk-dominated galaxies

The dominant role of mergers in the size evolution of massive early-type galaxies since z ∼ 1

Aims. The role of galaxy mergers in massive galaxy evolution, and in particular to mass assembly and size growth, remains an open question. In this paper we measure the merger fraction and rate, both minor and major, of massive early-type galaxies (M ⋆ ≥ 1011 M⊙) in the COSMOS field, and study their role in mass and size evolution. Methods. We used the 30-band photometric catalogue in COSMOS, complemented with the spectroscopy of the zCOSMOS survey, to define close pairs with a separation on the sky plane 10 h-1 kpc ≤ rp ≤ 30 h-1 kpc and a relative velocity Δv ≤ 500 km s-1 in redshift space. We measured both major (stellar mass ratio μ ≡ M ⋆ ,2/M ⋆ ,1 ≥ 1/4) and minor (1/10 ≤ μ < 1/4) merger fractions of massive galaxies, and studied their dependence on redshift and on morphology (early types vs. late types). Results. The merger fraction and rate of massive galaxies evolves as a power-law (1 + z)n, with major mergers increasing with redshift, nMM = 1.4, and minor mergers showing little evolution, nmm ~ 0. When split by their morphology, the minor merger fraction for early-type galaxies (ETGs) is higher by a factor of three than that for late-type galaxies (LTGs), and both are nearly constant with redshift. The fraction of major mergers for massive LTGs evolves faster (nMMLT ~ 4 ) than for ETGs (nMMET= 1.8). Conclusions. Our results show that massive ETGs have undergone 0.89 mergers (0.43 major and 0.46 minor) since z ~ 1, leading to a mass growth of ~30%. We find that μ ≥ 1/10 mergers can explain ~55% of the observed size evolution of these galaxies since z ~ 1. Another ~20% is due to the progenitor bias (younger galaxies are more extended) and we estimate that very minor mergers (μ < 1/10) could contribute with an extra ~20%. The remaining ~5% should come from other processes (e.g., adiabatic expansion or observational effects). This picture also reproduces the mass growth and the velocity dispersion evolution of these galaxies. We conclude from these results, and after exploring all the possible uncertainties in our picture, that merging is the main contributor to the size evolution of massive ETGs at z ≲ 1, accounting for ~50−75% of that evolution in the last 8 Gyr. Nearly half of the evolution due to mergers is related to minor (μ < 1/4) events

Improved constraints on the expansion rate of the Universe up to z ∼ 1.1 from the spectroscopic evolution of cosmic chronometers

We present new improved constraints on the Hubble parameter H(z) in the redshift range 0.15 < z < 1.1, obtained from the differential spectroscopic evolution of early-type galaxies as a function of redshift. We extract a large sample of early-type galaxies ( ∼ 11000) from several spectroscopic surveys, spanning almost 8 billion years of cosmic lookback time (0.15 < z < 1.42). We select the most massive, red elliptical galaxies, passively evolving and without signature of ongoing star formation. Those galaxies can be used as standard cosmic chronometers, as firstly proposed by Jimenez & Loeb (2002), whose differential age evolution as a function of cosmic time directly probes H(z). We analyze the 4000 Ã break (D4000) as a function of redshift, use stellar population synthesis models to theoretically calibrate the dependence of the differential age evolution on the differential D4000, and estimate the Hubble parameter taking into account both statistical and systematical errors. We provide 8 new measurements of H(z) (see table 4), and determine its change in H(z) to a precision of 5-12% mapping homogeneously the redshift range up to z ∼ 1.1; for the first time, we place a constraint on H(z) at z0 with a precision comparable with the one achieved for the Hubble constant (about 5-6% at z ∼ 0.2), and covered a redshift range (0.5 < z < 0.8) which is crucial to distinguish many different quintessence cosmologies. These measurements have been tested to best match a ΛCDM model, clearly providing a statistically robust indication that the Universe is undergoing an accelerated expansion. This method shows the potentiality to open a new avenue in constrain a variety of alternative cosmologies, especially when future surveys (e.g. Euclid) will open the possibility to extend it up to z ∼ 2

Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

Summary: Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients. Funding: Innovative Medicines Initiative 2 Joint Undertaking with support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study

Item does not contain fulltextOBJECTIVES: To provide a global, up-to-date picture of the prevalence, treatment, and outcomes of Candida bloodstream infections in intensive care unit patients and compare Candida with bacterial bloodstream infection. DESIGN: A retrospective analysis of the Extended Prevalence of Infection in the ICU Study (EPIC II). Demographic, physiological, infection-related and therapeutic data were collected. Patients were grouped as having Candida, Gram-positive, Gram-negative, and combined Candida/bacterial bloodstream infection. Outcome data were assessed at intensive care unit and hospital discharge. SETTING: EPIC II included 1265 intensive care units in 76 countries. PATIENTS: Patients in participating intensive care units on study day. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: Of the 14,414 patients in EPIC II, 99 patients had Candida bloodstream infections for a prevalence of 6.9 per 1000 patients. Sixty-one patients had candidemia alone and 38 patients had combined bloodstream infections. Candida albicans (n = 70) was the predominant species. Primary therapy included monotherapy with fluconazole (n = 39), caspofungin (n = 16), and a polyene-based product (n = 12). Combination therapy was infrequently used (n = 10). Compared with patients with Gram-positive (n = 420) and Gram-negative (n = 264) bloodstream infections, patients with candidemia were more likely to have solid tumors (p < .05) and appeared to have been in an intensive care unit longer (14 days [range, 5-25 days], 8 days [range, 3-20 days], and 10 days [range, 2-23 days], respectively), but this difference was not statistically significant. Severity of illness and organ dysfunction scores were similar between groups. Patients with Candida bloodstream infections, compared with patients with Gram-positive and Gram-negative bloodstream infections, had the greatest crude intensive care unit mortality rates (42.6%, 25.3%, and 29.1%, respectively) and longer intensive care unit lengths of stay (median [interquartile range]) (33 days [18-44], 20 days [9-43], and 21 days [8-46], respectively); however, these differences were not statistically significant. CONCLUSION: Candidemia remains a significant problem in intensive care units patients. In the EPIC II population, Candida albicans was the most common organism and fluconazole remained the predominant antifungal agent used. Candida bloodstream infections are associated with high intensive care unit and hospital mortality rates and resource use